Attention Deficit Hyperactivity Disorder (ADHD) News and Research

RSS

Attention Deficit Hyperactivity Disorder (ADHD)

Attention deficit-hyperactivity disorder (ADHD) is a neurobehavioral disorder that affects 3-5 percent of all American children. It interferes with a person's ability to stay on a task and to exercise age-appropriate inhibition (cognitive alone or both cognitive and behavioral).

Quality of care for ADHD children poor under Medicaid, says new report

Whatever its final incarnation, the recently enacted landmark Patient Protection and Affordable Care Act will expand Medicaid eligibility and is expected by 2013 to provide coverage, including mental health care, to an estimated 4.1 million children currently uninsured.

13 Dec 2010

Pisgah's technology imparts abuse deterrence to commonly abused prescription drugs

Pisgah Labs announced today the findings from a proof of concept study confirming Pisgah's technology imparts abuse deterrence to commonly abused prescription drugs, particularly narcotics. The controlled study, conducted in dogs, was performed with the un-formulated active ingredient, hydrocodone, as modified according to a host of patent applications filed by Pisgah Labs with the United States Patent and Trademark Office (http://www.uspto.gov).

10 Dec 2010

New software may help improve major deficiencies in ADHD children

An intensive, five-week working memory training program shows promise in relieving some of the symptoms of attention deficit hyperactivity disorder in children, a new study suggests.

10 Dec 2010

Urgent reform of Medicaid-financed community care for ADHD children needed

The enactment of the Patient Protection and Affordable Care Act of 2010 expands Medicare benefits to scores of previously uninsured individuals including many of our nation's children. While access to treatment is laudable, the quality of such treatment is the subject of an article in the December issue of the Journal of the American Academy of Child and Adolescent Psychiatry.

9 Dec 2010

ADHD, developmental RD have common genetic influences: Study

Attention Deficit Hyperactivity Disorder and developmental reading disability are complex childhood disorders that frequently occur together; if a child is experiencing trouble with reading, symptoms of ADHD are often also present.

9 Dec 2010

Intellipharmaceutics files generic 30 mg Focalin XR ANDA with FDA

Intellipharmaceutics International Inc., today announced that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for approval to market a generic of the 30 mg strength of Focalin XR® (dexmethylphenidate hydrochloride). The application for the 30 mg strength is filed as an amendment to the ANDA that Intellipharmaceutics had previously filed for the 5, 10, 15 and 20 mg strengths of the drug.

7 Dec 2010

ADHD drug market will decrease from $5 billion in 2009 to $4.1 billion in 2019: Report

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the attention-deficit/hyperactivity disorder (ADHD) drug market in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan will fluctuate modestly over the next decade, decreasing from $5 billion in 2009 to a trough in 2013 before climbing to $4.1 billion in 2019.

7 Dec 2010

Exposure to nicotine during pregnancy may cause learning disabilities in children: Research

Exposure to nicotine during pregnancy leads to a decrease in adult stem cells and a change in synaptic plasticity in the hippocampus of the offspring, according to new research from the University of Alabama at Birmingham presented at Neuroscience 2010, the annual Society for Neuroscience meeting in San Diego in November.

4 Dec 2010

Impax confirms challenge of patents in connection with INTUNIV

Impax Laboratories, Inc. today confirms that it has initiated a challenge of patents listed by Shire Development Inc. in connection with INTUNIVTM (guanfacine hydrochloride), 4 mg.

3 Dec 2010

Researchers develop best biologically based test for autism to date

Researchers at Harvard-affiliated McLean Hospital and the University of Utah have developed the best biologically based test for autism to date. The test was able to detect the disorder in individuals with high-functioning autism with 94 percent accuracy. The study will be published online the week of November 29th in Autism Research.

2 Dec 2010

Collegium completes spin-out of Onset Therapeutics

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, announced today that it has completed the spin-out of Onset Therapeutics, LLC, its wholly owned subsidiary focused on the Dermatology market.

2 Dec 2010

Neuroplasticity helps children with learning disabilities improve cognitive functioning capacities

Brain School, a new book from Eaton Arrowsmith School's (EAS) founder and director, Howard Eaton, tells the amazing story of how children with learning disabilities such as Dyslexia, Nonverbal Learning Disabilities and ADHD overcame educational obstacles by reorganizing their brains.

30 Nov 2010

Alza files patent infringement suit against Impax in connection with Concerta

Impax Laboratories, Inc. today confirms that Alza Corporation has filed suit for patent infringement against Impax in the United States District Court for the District of Delaware in connection with Concerta® (methylphenidate hydrochloride) extended-release 54 mg tablets.

30 Nov 2010

New pediatric therapy centres in Westmount and Pointe Claire

Parents know the joy when their child begins to lift their head, starts to turn over, say their first word and begins to read. For the family of a child who suffers from a developmental delay or disorder what happens after this discovery is not always simple. In many cases seeing a professional can be challenging. Collage Pediatric Therapy launched private pediatric therapy centres in Westmount and Pointe Claire to provide families with this additional resource and means of accessing the expertise and answers they need to be able to intervene at the earliest stage in their child's development.

25 Nov 2010

Shire announces FDA approval of Vyvanse Capsules CII for ADHD in adolescents

Shire plc, the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) approved the prescription medication Vyvanse® (lisdexamfetamine dimesylate) Capsules CII for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents ages 13 to 17. The approval is based on study data demonstrating that Vyvanse improved ADHD symptoms compared to placebo in adolescents with ADHD. Vyvanse is also indicated for the treatment of ADHD in children ages 6 to 12 years, and adults.

15 Nov 2010

Forest enters commercialization collaboration with Janssen for Bystolic and Savella in Canada

Forest Laboratories, Inc. announced that Forest Laboratories Holdings Limited, its wholly owned subsidiary, has entered into a definitive collaboration and distribution agreement for Bystolic® (nebivolol) and Savella® (milnacipran HCl) in Canada with Janssen Pharmaceutica, NV and Janssen Pharmaceutical respectively, on behalf of Janssen Inc., which will market the products in Canada.

12 Nov 2010

Children with hypertension more likely to have learning disabilities, ADHD

Children who have hypertension are much more likely to have learning disabilities than children with normal blood pressure, according to a new University of Rochester Medical Center (URMC) study published this week in the journal, Pediatrics. In fact, when variables such as socio-economic levels are evened out, children with hypertension were four times more likely to have cognitive problems.

10 Nov 2010

NeuroDerm commences enrollment in ND0801 Phase 2a clinical study of ADD/ADHD in adults

NeuroDerm, Ltd. announced today that patient enrollment has begun in a Phase 2a clinical study of ND0801, a new product for the treatment of Attention Deficit Disorder/Attention Deficit Hyperactivity Disorder (ADD/ADHD) in adults. ND0801, based on a new, proprietary combination with nicotinic actions, is being developed as a dermal patch and will be evaluated for the treatment of cognitive impairment in several disorders including Alzheimer's disease, schizophrenia and advanced Parkinson's disease, among others.

9 Nov 2010

Pisgah Labs receives QTDP grant to accelerate abuse deterrent technology

Pisgah Labs, Inc., an innovative drug development and active ingredient manufacturer located in Western North Carolina, has received a substantial federal grant.

4 Nov 2010

OMJPI enters agreement with Watson to distribute generic version of CONCERTA tablets

Ortho-McNeil-Janssen Pharmaceuticals, Inc. today announced it has entered into a supply and distribution agreement with Watson Laboratories, Inc. to distribute an authorized generic version of CONCERTA (methylphenidate HCl extended-release tablets).

3 Nov 2010